Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immuneering Corp

4.24
+0.11002.66%
Post-market: 4.17-0.0700-1.65%19:12 EDT
Volume:477.71K
Turnover:2.01M
Market Cap:152.58M
PE:-2.16
High:4.35
Open:4.23
Low:4.04
Close:4.13
Loading ...

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer

TIPRANKS
·
17 Jun

Immuneering Corp - 94% Os and 72% Pfs at 6 Months for Atebimetinib Combo

THOMSON REUTERS
·
17 Jun

Immuneering Corp - Pivotal Trial of Atebimetinib Combo in Pancreatic Cancer Planned for 2026

THOMSON REUTERS
·
17 Jun

Immuneering Corp - Additional Atebimetinib Clinical Trial Combination Arms to Initiate in 2026

THOMSON REUTERS
·
17 Jun

Immuneering Reports Positive Overall Survival Data for Atebimetinib (Imm-1-104) From Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

THOMSON REUTERS
·
17 Jun

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and KalVista Pharmaceuticals (KALV)

TIPRANKS
·
17 Jun

Immuneering Elects New Directors at Annual Meeting

TIPRANKS
·
16 Jun

Immuneering Corporation Conducted Annual Stockholders Meeting

Reuters
·
16 Jun

Immuneering Corporation to Share Phase 2a Clinical Trial Updates on IMM-1-104 for Pancreatic Cancer on June 17, 2025

Reuters
·
16 Jun

Immuneering to Provide Updates From Phase 2a Clinical Trial of Imm-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

THOMSON REUTERS
·
16 Jun

Immuneering Price Target Maintained With a $9.00/Share by Needham

Dow Jones
·
05 Jun

Positive Buy Rating for Immuneering Driven by Promising Clinical Data and Competitive Positioning

TIPRANKS
·
05 Jun

Immuneering Corporation to Present at Jefferies Global Healthcare Conference in New York City

Reuters
·
29 May

Immuneering Is Maintained at Outperform by Oppenheimer

Dow Jones
·
07 May

Immuneering Corporation : Oppenheimer Cuts Target Price to $21 From $25

THOMSON REUTERS
·
07 May

Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data

TIPRANKS
·
07 May

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 May

Immuneering Q1 EPS $(0.42) Beats $(0.58) Estimate

Benzinga
·
06 May

Immuneering Corp - Extends Cash Runway Into 2026

THOMSON REUTERS
·
06 May

Immuneering Corporation Q1 EPS USD -0.42

THOMSON REUTERS
·
06 May